Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 106Fallopian Tube Neoplasms 48Carcinoma, Ovarian Epithelial 31Uterine Cervical Neoplasms 28Pancreatic Neoplasms 13Endometrial Neoplasms 13Neoplasms 10Colorectal Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 10Recurrence 7Prostatic Neoplasms 7Neoplasm Metastasis 7Lung Neoplasms 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Sarcoma 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Peritoneal Neoplasms 5Cholangiocarcinoma 5Small Cell Lung Carcinoma 4Melanoma 4Head and Neck Neoplasms 4Esophageal Neoplasms 4Colonic Neoplasms 4Vulvar Neoplasms 3Uterine Neoplasms 3Multiple Myeloma 3Carcinoma 3

Interventions

pembrolizumab 3lenvatinib 2Injections 2anlotinib 1Paclitaxel 1NVP-BKM120 1Gemcitabine 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Endometrial Cancer × Gemcitabine × Gynecologic × Clear all
NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
71 enrolled
GynecologicSarcoma

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡